Skip to main content
Erschienen in: Heart and Vessels 2/2018

16.08.2017 | Original Article

Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry

verfasst von: Michiyo Shiiba, Bo Zhang, Shin-ichiro Miura, Amane Ike, Daisuke Nose, Takashi Kuwano, Satoshi Imaizumi, Makoto Sugihara, Atushi Iwata, Hiroaki Nishikawa, Akira Kawamura, Kazuyuki Shirai, Shin’ichiro Yasunaga, Keijiro Saku

Erschienen in: Heart and Vessels | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

It is not yet clear whether the discordance of low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) predicts the follow-up clinical outcome (major adverse cardiovascular events: MACEs) in patients with coronary stent implantation. Among 2015 patients with coronary stent implantation (Fukuoka University [FU]-Registry), excluding those with acute coronary syndrome or hemodialysis, we selected 801 patients who had undergone successful stent implantation with a follow-up until 18 months, and classified them into 3 groups according to baseline LDL-C and non-HDL-C levels [percentile(P)non-HDL-C more than (P)LDL-C, (P)non-HDL-C equal to (P)LDL-C, and (P)non-HDL-C less than (P) LDL-C]. We found that the discordance of (P)LDL-C and (P)non-HDL-C was not a significant predictor of MACEs. Higher LDL-C level was consistently and independently associated with higher incidences of MACEs after controlling for conventional risk factors and the type of stent used by multivariate Cox regression analyses. In conclusion, LDL-C levels are more important than non-HDL-C levels and the discordance of LDL-C and non-HDL-C levels as predictors of MACEs in patients with stable angina after stent implantation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368:1155–1163CrossRefPubMed Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368:1155–1163CrossRefPubMed
2.
Zurück zum Zitat Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JS (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207CrossRefPubMed Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JS (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207CrossRefPubMed
3.
Zurück zum Zitat LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets I (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435CrossRefPubMed LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets I (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435CrossRefPubMed
4.
Zurück zum Zitat Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, and Incremental Decrease in End Points Through Aggressive Lipid Lowering Study G (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437–2445CrossRef Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, and Incremental Decrease in End Points Through Aggressive Lipid Lowering Study G (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437–2445CrossRef
5.
Zurück zum Zitat Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin E, and Infection Therapy-Thrombolysis in Myocardial Infarction I (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504CrossRefPubMed Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin E, and Infection Therapy-Thrombolysis in Myocardial Infarction I (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504CrossRefPubMed
6.
Zurück zum Zitat Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM, Group TNTS, Group IS (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117:3002–3009CrossRefPubMed Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM, Group TNTS, Group IS (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117:3002–3009CrossRefPubMed
7.
Zurück zum Zitat National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A (2002) Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421 National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A (2002) Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
8.
Zurück zum Zitat Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, European Society of C, and European Atherosclerosis S (2011) ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217:3CrossRefPubMed Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, European Society of C, and European Atherosclerosis S (2011) ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217:3CrossRefPubMed
9.
Zurück zum Zitat Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
10.
Zurück zum Zitat Sniderman AD, Lamarche B, Contois JH, de Graaf J (2014) Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Curr Opin Lipidol 25:461–467CrossRefPubMed Sniderman AD, Lamarche B, Contois JH, de Graaf J (2014) Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Curr Opin Lipidol 25:461–467CrossRefPubMed
11.
Zurück zum Zitat Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD (2011) A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 4:337–345CrossRefPubMed Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD (2011) A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 4:337–345CrossRefPubMed
12.
Zurück zum Zitat Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL (2001) Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161:1413–1419CrossRefPubMed Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL (2001) Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161:1413–1419CrossRefPubMed
13.
Zurück zum Zitat Sniderman AD, Islam S, Yusuf S, McQueen MJ (2013) Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables? J Clin Lipidol 7:626–631CrossRefPubMed Sniderman AD, Islam S, Yusuf S, McQueen MJ (2013) Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables? J Clin Lipidol 7:626–631CrossRefPubMed
14.
Zurück zum Zitat Mora S, Buring JE, Ridker PM (2014) Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 129:553–561CrossRefPubMed Mora S, Buring JE, Ridker PM (2014) Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 129:553–561CrossRefPubMed
15.
Zurück zum Zitat Ike A, Shirai K, Nishikawa H, Iwata A, Yahiro E, Sugihara M, Kawamura A, Uehara Y, Zhang B, Ogawa M, Mori K, Miura S, Saku K (2015) Associations between different types of hypoglycemic agents and the clinical outcome of percutaneous coronary intervention in diabetic patients-from the FU-Registry. J Cardiol 65:390–396CrossRefPubMed Ike A, Shirai K, Nishikawa H, Iwata A, Yahiro E, Sugihara M, Kawamura A, Uehara Y, Zhang B, Ogawa M, Mori K, Miura S, Saku K (2015) Associations between different types of hypoglycemic agents and the clinical outcome of percutaneous coronary intervention in diabetic patients-from the FU-Registry. J Cardiol 65:390–396CrossRefPubMed
16.
Zurück zum Zitat Ike A, Nishikawa H, Shirai K, Mori K, Kuwano T, Fukuda Y, Takamiya Y, Yanagi D, Kubota K, Tsuchiya Y, Zhang B, Miura S, Saku K (2011) Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention—from the FU-registry. Circ J 75:791–799CrossRefPubMed Ike A, Nishikawa H, Shirai K, Mori K, Kuwano T, Fukuda Y, Takamiya Y, Yanagi D, Kubota K, Tsuchiya Y, Zhang B, Miura S, Saku K (2011) Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention—from the FU-registry. Circ J 75:791–799CrossRefPubMed
17.
Zurück zum Zitat Nagata I, Ike A, Nishikawa H, Zhang B, Sugihara M, Mori K, Iwata A, Kawamura A, Shirai K, Uehara Y, Ogawa M, Miura S, Saku K (2015) Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention: from the FU-Registry. J Cardiol 65:105–111CrossRefPubMed Nagata I, Ike A, Nishikawa H, Zhang B, Sugihara M, Mori K, Iwata A, Kawamura A, Shirai K, Uehara Y, Ogawa M, Miura S, Saku K (2015) Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention: from the FU-Registry. J Cardiol 65:105–111CrossRefPubMed
19.
Zurück zum Zitat Sniderman AD, Islam S, Yusuf S, McQueen MJ (2012) Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis 225:444–449CrossRefPubMed Sniderman AD, Islam S, Yusuf S, McQueen MJ (2012) Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis 225:444–449CrossRefPubMed
20.
Zurück zum Zitat Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr (2011) Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 5:105–113CrossRefPubMedPubMedCentral Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr (2011) Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 5:105–113CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Westfall PH, Tobias RD, Wolfinger RD (2011) Multiple Comparisons and Multiple Tests Using SAS, 2nd edn. SAS Institute Inc., Cary, pp 273–289 Westfall PH, Tobias RD, Wolfinger RD (2011) Multiple Comparisons and Multiple Tests Using SAS, 2nd edn. SAS Institute Inc., Cary, pp 273–289
22.
Zurück zum Zitat Allison PD (2010) Survival analysis using SAS. A practical guide, 2nd edn. SAS Institute Inc., Cary, pp 204–233 Allison PD (2010) Survival analysis using SAS. A practical guide, 2nd edn. SAS Institute Inc., Cary, pp 204–233
23.
Zurück zum Zitat Matange S, Heath D (2011) Statistical graphics procedures by example: effective graphs using SAS, 2nd edn. SAS Institute Inc., Cary, pp 61–88 Matange S, Heath D (2011) Statistical graphics procedures by example: effective graphs using SAS, 2nd edn. SAS Institute Inc., Cary, pp 61–88
24.
Zurück zum Zitat Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice G (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:2889–2934CrossRefPubMed Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice G (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:2889–2934CrossRefPubMed
25.
Zurück zum Zitat Sniderman A, McQueen M, Contois J, Williams K, Furberg CD (2010) Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol 4:152–155CrossRefPubMed Sniderman A, McQueen M, Contois J, Williams K, Furberg CD (2010) Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol 4:152–155CrossRefPubMed
26.
Zurück zum Zitat Lawler PR, Akinkuolie AO, Ridker PM, Sniderman AD, Buring JE, Glynn RJ, Chasman DI, Mora S (2017) Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women. Clin Chem 63:870–879CrossRefPubMed Lawler PR, Akinkuolie AO, Ridker PM, Sniderman AD, Buring JE, Glynn RJ, Chasman DI, Mora S (2017) Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women. Clin Chem 63:870–879CrossRefPubMed
27.
Zurück zum Zitat Saku K, Zhang B, Noda K, Investigators PT (2011) Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 75:1493–1505CrossRefPubMed Saku K, Zhang B, Noda K, Investigators PT (2011) Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 75:1493–1505CrossRefPubMed
28.
Zurück zum Zitat Zhang B, Matsunaga A, Rainwater DL, Miura S, Noda K, Nishikawa H, Uehara Y, Shirai K, Ogawa M, Saku K (2009) Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study. J Lipid Res 50:1832–1841CrossRefPubMedPubMedCentral Zhang B, Matsunaga A, Rainwater DL, Miura S, Noda K, Nishikawa H, Uehara Y, Shirai K, Ogawa M, Saku K (2009) Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study. J Lipid Res 50:1832–1841CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Zhang B, Miura S, Yanagi D, Noda K, Nishikawa H, Matsunaga A, Shirai K, Iwata A, Yoshinaga K, Adachi H, Imaizumi T, Saku K (2008) Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study. Atherosclerosis 201:353–359CrossRefPubMed Zhang B, Miura S, Yanagi D, Noda K, Nishikawa H, Matsunaga A, Shirai K, Iwata A, Yoshinaga K, Adachi H, Imaizumi T, Saku K (2008) Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study. Atherosclerosis 201:353–359CrossRefPubMed
30.
Zurück zum Zitat Zhang B, Katafuchi R, Arishima H, Matsunaga A, Rye KA, Saku K (2006) Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis. Clin Chim Acta 373:55–61CrossRefPubMed Zhang B, Katafuchi R, Arishima H, Matsunaga A, Rye KA, Saku K (2006) Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis. Clin Chim Acta 373:55–61CrossRefPubMed
Metadaten
Titel
Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry
verfasst von
Michiyo Shiiba
Bo Zhang
Shin-ichiro Miura
Amane Ike
Daisuke Nose
Takashi Kuwano
Satoshi Imaizumi
Makoto Sugihara
Atushi Iwata
Hiroaki Nishikawa
Akira Kawamura
Kazuyuki Shirai
Shin’ichiro Yasunaga
Keijiro Saku
Publikationsdatum
16.08.2017
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 2/2018
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-017-1036-x

Weitere Artikel der Ausgabe 2/2018

Heart and Vessels 2/2018 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.